Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.
Identifieur interne : 000D08 ( Ncbi/Merge ); précédent : 000D07; suivant : 000D09Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.
Auteurs : Damien Toulorge [France] ; Serge Guerreiro ; Audrey Hild ; Uwe Maskos ; Etienne C. Hirsch ; Patrick P. MichelSource :
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology [ 1530-6860 ] ; 2011.
English descriptors
- KwdEn :
- Animals, Calcium (metabolism), Calcium Channels, T-Type (metabolism), Calmodulin (metabolism), Cell Survival (drug effects), Cytoplasm (metabolism), Dopamine (metabolism), Glial Cell Line-Derived Neurotrophic Factor (metabolism), Ion Channel Gating (drug effects), Mesencephalon (cytology), Mesencephalon (drug effects), Mesencephalon (metabolism), Mice, Models, Neurological, Neurons (drug effects), Neurons (metabolism), Neuroprotective Agents (pharmacology), Nicotine (pharmacology), Potassium Channel Blockers (pharmacology), Proto-Oncogene Proteins c-akt (metabolism), Rats, Receptors, Nicotinic (metabolism), Signal Transduction (drug effects), Tetraethylammonium (pharmacology), Tissue Culture Techniques, alpha7 Nicotinic Acetylcholine Receptor.
- MESH :
- chemical , metabolism : Calcium, Calcium Channels, T-Type, Calmodulin, Dopamine, Glial Cell Line-Derived Neurotrophic Factor, Proto-Oncogene Proteins c-akt, Receptors, Nicotinic.
- cytology : Mesencephalon.
- drug effects : Cell Survival, Ion Channel Gating, Mesencephalon, Neurons, Signal Transduction.
- metabolism : Cytoplasm, Mesencephalon, Neurons.
- chemical , pharmacology : Neuroprotective Agents, Nicotine, Potassium Channel Blockers, Tetraethylammonium.
- Animals, Mice, Models, Neurological, Rats, Tissue Culture Techniques, alpha7 Nicotinic Acetylcholine Receptor.
Abstract
Epidemiological and experimental evidence indicates that nicotine is protective for Parkinson disease vulnerable dopamine neurons, but the underlying mechanism of this effect remains only partly characterized. To address this question, we established rat midbrain cultures maintained in experimental conditions that favor the selective and spontaneous loss of dopamine neurons. We report here that nicotine afforded neuroprotection to dopamine neurons (EC(50)=0.32 μM) but only in a situation where cytosolic Ca(2+) (Ca(2+)(cyt)) was slightly and chronically elevated above control levels by concurrent depolarizing treatments. By a pharmacological approach, we demonstrated that the rise in Ca(2+)(cyt) was necessary to sensitize dopamine neurons to the action of nicotine through a mechanism involving α-bungarotoxin-sensitive (presumably α7) nicotinic acetylcholine receptors (nAChRs) and secondarily T-type voltage-gated calcium channels. Confirming the role played by α7 nAChRs in this effect, nicotine had no protective action in midbrain cultures prepared from genetically engineered mice lacking this receptor subtype. Signaling studies revealed that Ca(2+)(cyt) elevations evoked by nicotine and concomitant depolarizing treatments served to activate a survival pathway involving the calcium effector protein calmodulin and phosphatidylinositol 3-kinase. Collectively, our data support the idea that the protective action of nicotine for dopamine neurons is activity-dependent and gated by Ca(2+)(cyt).
DOI: 10.1096/fj.11-182824
PubMed: 21507900
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000954
- to stream PubMed, to step Curation: 000914
- to stream PubMed, to step Checkpoint: 000914
Links to Exploration step
pubmed:21507900Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.</title><author><name sortKey="Toulorge, Damien" sort="Toulorge, Damien" uniqKey="Toulorge D" first="Damien" last="Toulorge">Damien Toulorge</name><affiliation wicri:level="3"><nlm:affiliation>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Unité Mixte de Recherche-S975, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Unité Mixte de Recherche-S975, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Guerreiro, Serge" sort="Guerreiro, Serge" uniqKey="Guerreiro S" first="Serge" last="Guerreiro">Serge Guerreiro</name></author><author><name sortKey="Hild, Audrey" sort="Hild, Audrey" uniqKey="Hild A" first="Audrey" last="Hild">Audrey Hild</name></author><author><name sortKey="Maskos, Uwe" sort="Maskos, Uwe" uniqKey="Maskos U" first="Uwe" last="Maskos">Uwe Maskos</name></author><author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C" last="Hirsch">Etienne C. Hirsch</name></author><author><name sortKey="Michel, Patrick P" sort="Michel, Patrick P" uniqKey="Michel P" first="Patrick P" last="Michel">Patrick P. Michel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21507900</idno><idno type="pmid">21507900</idno><idno type="doi">10.1096/fj.11-182824</idno><idno type="wicri:Area/PubMed/Corpus">000954</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000954</idno><idno type="wicri:Area/PubMed/Curation">000914</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000914</idno><idno type="wicri:Area/PubMed/Checkpoint">000914</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000914</idno><idno type="wicri:Area/Ncbi/Merge">000D08</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.</title><author><name sortKey="Toulorge, Damien" sort="Toulorge, Damien" uniqKey="Toulorge D" first="Damien" last="Toulorge">Damien Toulorge</name><affiliation wicri:level="3"><nlm:affiliation>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Unité Mixte de Recherche-S975, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Unité Mixte de Recherche-S975, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Guerreiro, Serge" sort="Guerreiro, Serge" uniqKey="Guerreiro S" first="Serge" last="Guerreiro">Serge Guerreiro</name></author><author><name sortKey="Hild, Audrey" sort="Hild, Audrey" uniqKey="Hild A" first="Audrey" last="Hild">Audrey Hild</name></author><author><name sortKey="Maskos, Uwe" sort="Maskos, Uwe" uniqKey="Maskos U" first="Uwe" last="Maskos">Uwe Maskos</name></author><author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C" last="Hirsch">Etienne C. Hirsch</name></author><author><name sortKey="Michel, Patrick P" sort="Michel, Patrick P" uniqKey="Michel P" first="Patrick P" last="Michel">Patrick P. Michel</name></author></analytic><series><title level="j">FASEB journal : official publication of the Federation of American Societies for Experimental Biology</title><idno type="eISSN">1530-6860</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Calcium (metabolism)</term><term>Calcium Channels, T-Type (metabolism)</term><term>Calmodulin (metabolism)</term><term>Cell Survival (drug effects)</term><term>Cytoplasm (metabolism)</term><term>Dopamine (metabolism)</term><term>Glial Cell Line-Derived Neurotrophic Factor (metabolism)</term><term>Ion Channel Gating (drug effects)</term><term>Mesencephalon (cytology)</term><term>Mesencephalon (drug effects)</term><term>Mesencephalon (metabolism)</term><term>Mice</term><term>Models, Neurological</term><term>Neurons (drug effects)</term><term>Neurons (metabolism)</term><term>Neuroprotective Agents (pharmacology)</term><term>Nicotine (pharmacology)</term><term>Potassium Channel Blockers (pharmacology)</term><term>Proto-Oncogene Proteins c-akt (metabolism)</term><term>Rats</term><term>Receptors, Nicotinic (metabolism)</term><term>Signal Transduction (drug effects)</term><term>Tetraethylammonium (pharmacology)</term><term>Tissue Culture Techniques</term><term>alpha7 Nicotinic Acetylcholine Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Calcium</term><term>Calcium Channels, T-Type</term><term>Calmodulin</term><term>Dopamine</term><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Proto-Oncogene Proteins c-akt</term><term>Receptors, Nicotinic</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Mesencephalon</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Survival</term><term>Ion Channel Gating</term><term>Mesencephalon</term><term>Neurons</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cytoplasm</term><term>Mesencephalon</term><term>Neurons</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuroprotective Agents</term><term>Nicotine</term><term>Potassium Channel Blockers</term><term>Tetraethylammonium</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Mice</term><term>Models, Neurological</term><term>Rats</term><term>Tissue Culture Techniques</term><term>alpha7 Nicotinic Acetylcholine Receptor</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Epidemiological and experimental evidence indicates that nicotine is protective for Parkinson disease vulnerable dopamine neurons, but the underlying mechanism of this effect remains only partly characterized. To address this question, we established rat midbrain cultures maintained in experimental conditions that favor the selective and spontaneous loss of dopamine neurons. We report here that nicotine afforded neuroprotection to dopamine neurons (EC(50)=0.32 μM) but only in a situation where cytosolic Ca(2+) (Ca(2+)(cyt)) was slightly and chronically elevated above control levels by concurrent depolarizing treatments. By a pharmacological approach, we demonstrated that the rise in Ca(2+)(cyt) was necessary to sensitize dopamine neurons to the action of nicotine through a mechanism involving α-bungarotoxin-sensitive (presumably α7) nicotinic acetylcholine receptors (nAChRs) and secondarily T-type voltage-gated calcium channels. Confirming the role played by α7 nAChRs in this effect, nicotine had no protective action in midbrain cultures prepared from genetically engineered mice lacking this receptor subtype. Signaling studies revealed that Ca(2+)(cyt) elevations evoked by nicotine and concomitant depolarizing treatments served to activate a survival pathway involving the calcium effector protein calmodulin and phosphatidylinositol 3-kinase. Collectively, our data support the idea that the protective action of nicotine for dopamine neurons is activity-dependent and gated by Ca(2+)(cyt).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21507900</PMID><DateCreated><Year>2011</Year><Month>08</Month><Day>02</Day></DateCreated><DateCompleted><Year>2011</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J.</ISOAbbreviation></Journal><ArticleTitle>Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.</ArticleTitle><Pagination><MedlinePgn>2563-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.11-182824</ELocationID><Abstract><AbstractText>Epidemiological and experimental evidence indicates that nicotine is protective for Parkinson disease vulnerable dopamine neurons, but the underlying mechanism of this effect remains only partly characterized. To address this question, we established rat midbrain cultures maintained in experimental conditions that favor the selective and spontaneous loss of dopamine neurons. We report here that nicotine afforded neuroprotection to dopamine neurons (EC(50)=0.32 μM) but only in a situation where cytosolic Ca(2+) (Ca(2+)(cyt)) was slightly and chronically elevated above control levels by concurrent depolarizing treatments. By a pharmacological approach, we demonstrated that the rise in Ca(2+)(cyt) was necessary to sensitize dopamine neurons to the action of nicotine through a mechanism involving α-bungarotoxin-sensitive (presumably α7) nicotinic acetylcholine receptors (nAChRs) and secondarily T-type voltage-gated calcium channels. Confirming the role played by α7 nAChRs in this effect, nicotine had no protective action in midbrain cultures prepared from genetically engineered mice lacking this receptor subtype. Signaling studies revealed that Ca(2+)(cyt) elevations evoked by nicotine and concomitant depolarizing treatments served to activate a survival pathway involving the calcium effector protein calmodulin and phosphatidylinositol 3-kinase. Collectively, our data support the idea that the protective action of nicotine for dopamine neurons is activity-dependent and gated by Ca(2+)(cyt).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toulorge</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Unité Mixte de Recherche-S975, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hild</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Maskos</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Etienne C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Patrick P</ForeName><Initials>PP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020747">Calcium Channels, T-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002147">Calmodulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579166">Chrna7 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579165">Chrna7 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064569">alpha7 Nicotinic Acetylcholine Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>66-40-0</RegistryNumber><NameOfSubstance UI="D019789">Tetraethylammonium</NameOfSubstance></Chemical><Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020747" MajorTopicYN="N">Calcium Channels, T-Type</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002147" MajorTopicYN="N">Calmodulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015640" MajorTopicYN="N">Ion Channel Gating</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019789" MajorTopicYN="N">Tetraethylammonium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046509" MajorTopicYN="N">Tissue Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064569" MajorTopicYN="N">alpha7 Nicotinic Acetylcholine Receptor</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21507900</ArticleId><ArticleId IdType="pii">fj.11-182824</ArticleId><ArticleId IdType="doi">10.1096/fj.11-182824</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Guerreiro, Serge" sort="Guerreiro, Serge" uniqKey="Guerreiro S" first="Serge" last="Guerreiro">Serge Guerreiro</name><name sortKey="Hild, Audrey" sort="Hild, Audrey" uniqKey="Hild A" first="Audrey" last="Hild">Audrey Hild</name><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C" last="Hirsch">Etienne C. Hirsch</name><name sortKey="Maskos, Uwe" sort="Maskos, Uwe" uniqKey="Maskos U" first="Uwe" last="Maskos">Uwe Maskos</name><name sortKey="Michel, Patrick P" sort="Michel, Patrick P" uniqKey="Michel P" first="Patrick P" last="Michel">Patrick P. Michel</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Toulorge, Damien" sort="Toulorge, Damien" uniqKey="Toulorge D" first="Damien" last="Toulorge">Damien Toulorge</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D08 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000D08 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:21507900
|texte= Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:21507900" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |